SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp tech- and AI-led selloff has fueled fears of further downside, with traders debating whether Black Monday anniversary concerns and AI-related debt risks signal a broader market break. Others point to a strong futures rebound and see a possible relief bounce, while doubting it confirms a lasting recovery.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

A sharp market pullback and a subsequent surge in futures have sparked debate over whether the rebound reflects dip-buying and short covering or a temporary bull trap. Traders are also pushing back against Black Monday crash fears, while bearish voices point to lingering downside risk and volatility.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is caught in a sharp selloff across AI infrastructure and neocloud stocks, as traders worry about debt-funded data-center expansion, financing costs, and whether AI spending can deliver adequate returns. Bulls argue Nebius has a stronger balance sheet and long-term compute demand than more leveraged peers, while bears see broader sector risks and further valuation pressure; claims of forced liquidations or deliberate market manipulation remain speculation.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

A sharp semiconductor-sector selloff has put SOXL, a 3 leveraged ETF, under pressure, with traders debating whether concerns about AI spending, debt, inflation and Chinese chip competition signal deeper losses or an oversold dip. The community is split between buying for a rebound and warning that continued volatility could bring further downside.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

Hotter-than-expected inflation readings and renewed Fed tightening concerns have weighed on rate-sensitive small caps, while technical weakness has added to pressure on IWM. Traders are divided between looking for an oversold bounce and expecting further declines if support fails.

Canadian Solar, Inc. engages in the manufacture of solar photovoltaic modules, provision of solar energy and battery storage solutions, and development of utility-scale solar and battery storage products. It operates through the CSI Solar and Global Energy segments. The CSI Solar segment designs, develops, and manufactures solar ingots, wafers, cells, modules, and other solar power and battery storage products. The Global Energy segment includes solar and battery storage project development and sale, asset management services for operational projects, sale of electricity, and investment in retained assets. The company was founded by Shawn Qu in October 2001 and is headquartered in Kitchener, Canada.

Canadian Solar Inc

Chinas proposed export controls on solar-manufacturing technologies, including HJT, have put Canadian Solars U.S. cell expansion in focus. Traders debate whether the restrictions could complicate technology access or make its Jeffersonville facility more valuable, while broader optimism about short-squeeze potential is countered by concerns over losses, debt, and execution.

Tidal Trust II - YieldMax Semiconductor Portfolio Option Income ETF

YieldMax Semiconductor Portfolio Option Income ETF

A semiconductor-sector pullback is weighing on CHPY, with traders linking its decline to weakness in chip and AI-related stocks. Many are treating the dip as a chance to accumulate for the funds weekly distributions, while others worry about further price declines and whether the payouts can offset NAV erosion.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs Phase 3 REGAL trial is the focus, with the final analysis awaiting the 80th overall-survival event; the last publicly reported count was 78, and the company has not confirmed that the trigger has occurred. Traders are split over the prolonged wait: some see extended patient survival as a possible positive signal, while others worry about trial uncertainty and company silence, amid a sharp share-price decline and speculation about options-related pressure.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Anticipation around Cleveland-Cliffs Q3 earnings is driving attention, with bullish traders citing elevated steel prices and contract resets as potential support for a return to profitability and debt reduction, while skeptics question whether those tailwinds can overcome the companys debt and execution challenges. Short-squeeze expectations are also circulating, but remain speculative.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

Deltas quarterly earnings miss and reduced full-year profit outlook, driven by surging jet-fuel costs, are weighing on shares despite strong travel demand and premium revenue. Traders are divided between concerns that fuel and other expenses will keep squeezing margins and the view that resilient bookings and pricing power could support a recovery.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue Estimates

CAMP4 Therapeutics Corporation (CAMP) delivered earnings and revenue surprises of +8.33% and +31.78%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Ocugen (OCGN) Reports Q2 Loss, Beats Revenue Estimates

Ocugen (OCGN) delivered earnings and revenue surprises of -40.00% and +6.29%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

MannKind (MNKD) Reports Q2 Loss, Beats Revenue Estimates

MannKind (MNKD) delivered earnings and revenue surprises of -200.00% and +2.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Tops Revenue Estimates

CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of +14.55% and +37.28%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

CAMP Expands Its Team as the Race to Unlock Next-Generation RNA Therapeutics Accelerates

Talent is often one of the earliest indicators of a biotechnology company's long-term ambitions. That theme was reinforced this week as CAMP4 Therapeutics (NASDAQ:CAMP) announced an inducement equity award to a newly hired employee under Nasdaq Listing Rule 5635(c)(4), a standard mechanism that allows listed companies to use equity grants as a recruiting incentive for new hires. While modest in size, an option to purchase 8,000 shares, the announcement signals continued investment in building the team behind CAMP4's clinical-stage pipeline.

New Strong Sell Stocks for July 16th

AYTU, CAMP and CRC have been added to the Zacks Rank #5 (Strong Sell) List on July 16, 2026.

CAMP4 Therapeutics Corporation (CAMP) Reports Q1 Loss, Lags Revenue Estimates

CAMP4 Therapeutics Corporation (CAMP) delivered earnings and revenue surprises of -49.53% and -22.19%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Short Interest in CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Expands By 13.1%

CAMP4 Therapeutics Corporation (NASDAQ:CAMP - Get Free Report) was the target of a large increase in short interest in the month of April. As of April 15th, there was short interest totaling 468,369...

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Short Interest Down 14.2% in March

CAMP4 Therapeutics Corporation (NASDAQ:CAMP - Get Free Report) was the target of a large decrease in short interest in March. As of March 31st, there was short interest totaling 414,235 shares, a decrease of 14.2% from the March 15th total of 483,060 shares. Based on an average daily trading...

CAMP4 Therapeutics (NASDAQ:CAMP) Upgraded to "Strong-Buy" at Rodman & Renshaw

Rodman & Renshaw upgraded CAMP4 Therapeutics to a "strong-buy" rating in a research report on Tuesday...

CAMP4 Therapeutics Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a class of RNA-targeting therapeutics for upregulating gene expression and restoration of healthy protein levels to treat a broad range of genetic diseases. Its lead product candidate is CMP-002. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.

CAMP4 Therapeutics Corp.

Bullish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$3.17
Prev Close	$3.45
Open	$3.45
Dividend Yield	0.00%
50-Day Moving Average	$4.12
Beta	1.61
Avg. Volume	282,125.50
PE Ratio	-1.42

52-Week High	$7.75
52-Week Low	$2.88
Market Capitalization	$198.93M
EPS (Annual)	-$2.65
Price to Book	-237.45
Revenue Per Employee	$72,875.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

CAMP Fundamentals